Back to top
more

Erasca (ERAS)

(Real Time Quote from BATS)

$1.82 USD

1.82
36,048

-0.06 (-3.19%)

Updated Apr 25, 2024 10:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stocks to Buy for April 23rd

by Zacks Equity Research

FSM, LPX and ERAS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2024.

New Strong Buy Stocks for April 23rd

by Zacks Equity Research

CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024.

J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps

by Zacks Equity Research

J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.

Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal

by Zacks Equity Research

Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.

Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss

by Zacks Equity Research

Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.

Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 125.9% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why Erasca, Inc. (ERAS) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Erasca, Inc. (ERAS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Wall Street Analysts See an 111% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at an 111.1% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 244%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 244% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Erasca, Inc. (ERAS) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Erasca, Inc. (ERAS) closed at $8.11 in the latest trading session, marking a +1.88% move from the prior day.

Erasca, Inc. (ERAS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Erasca, Inc. (ERAS) closed the most recent trading day at $7.77, moving -1.4% from the previous trading session.

Erasca, Inc. (ERAS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Erasca, Inc. (ERAS) closed at $6.72, marking a +1.05% move from the previous day.

Wall Street Analysts See a 288% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 288% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Erasca, Inc. (ERAS) Stock Moves -0.32%: What You Should Know

by Zacks Equity Research

Erasca, Inc. (ERAS) closed the most recent trading day at $6.27, moving -0.32% from the previous trading session.

Erasca, Inc. (ERAS) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Erasca, Inc. (ERAS) closed the most recent trading day at $6.16, moving +1.65% from the previous trading session.

Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 362%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 361.8% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Erasca, Inc. (ERAS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Erasca, Inc. (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Company News for Mar 28, 2022

by Zacks Equity Research

Companies In The News Are: DOOO, BBBY, SMRT, ERAS.

Is a Surprise Coming for Erasca (ERAS) This Earnings Season?

by Zacks Equity Research

Erasca (ERAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study

by Zacks Equity Research

Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.